Nat Commun:PTEN-ARID4B-PI3K途径鉴定了PTEN缺陷前列腺癌对ARID4B的依赖性

2019-10-06 AlexYang MedSci原创

在前列腺癌中,PTEN经常发生变异。PTEN的肿瘤抑制子功能归结于其脂肪磷酸化活性且能够拮抗PI3K的作用。最近,有研究人员报道了PTEN-ARID4B-PI3K途径,其中PTEN能够抑制ARID4B的表达,而ARID4B是PI3K亚单元基因PIK3CA和PIK3R2的转录激活因子,且亚单元基因PIK3CA和PIK3R2对PI3K/AKT途径的激活是非常关键的。ARID4B和组蛋白H1结合到PIK

在前列腺癌中,PTEN经常发生变异。PTEN的肿瘤抑制子功能归结于其脂肪磷酸化活性且能够拮抗PI3K的作用。

最近,有研究人员报道了PTEN-ARID4B-PI3K途径,其中PTEN能够抑制ARID4B的表达,而ARID4B是PI3K亚单元基因PIK3CA和PIK3R2的转录激活因子,且亚单元基因PIK3CA和PIK3R2对PI3K/AKT途径的激活是非常关键的。ARID4B和组蛋白H1结合到PIK3CA和PIK3R2的启动子能够调控染色质凝聚,表明了ARID4B能够激活这些启动子的机制。功能分析阐释了当PTEN缺失时,ARID4B对前列腺的致瘤作用是需要的。另外,PTEN/ARID4B/PI3K3CA的生物学意义进一步表现在能够增强患者前列腺癌复发预测的能力。

最后,研究人员指出,他们鉴定了ARID4B是PTEN-PI3K途径中的主调控因子,因此为携带PTEN变异的前列腺提供了新的治疗靶标。

原始出处:

Ray-Chang Wu, In-Chi Young, Yu-Fang Chen et al. Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer. Nat Commun. 24 Sep 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883904, encodeId=b76c18839049c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 08 23:02:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087602, encodeId=487c208e60296, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jan 05 17:02:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315941, encodeId=ce6c1315941eb, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Oct 08 13:02:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333229, encodeId=d60013332295b, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Oct 08 13:02:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040562, encodeId=1ed8104056249, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Oct 07 01:02:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2020-05-08 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883904, encodeId=b76c18839049c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 08 23:02:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087602, encodeId=487c208e60296, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jan 05 17:02:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315941, encodeId=ce6c1315941eb, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Oct 08 13:02:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333229, encodeId=d60013332295b, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Oct 08 13:02:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040562, encodeId=1ed8104056249, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Oct 07 01:02:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2020-01-05 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883904, encodeId=b76c18839049c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 08 23:02:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087602, encodeId=487c208e60296, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jan 05 17:02:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315941, encodeId=ce6c1315941eb, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Oct 08 13:02:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333229, encodeId=d60013332295b, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Oct 08 13:02:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040562, encodeId=1ed8104056249, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Oct 07 01:02:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2019-10-08 智智灵药
  4. [GetPortalCommentsPageByObjectIdResponse(id=1883904, encodeId=b76c18839049c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 08 23:02:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087602, encodeId=487c208e60296, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jan 05 17:02:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315941, encodeId=ce6c1315941eb, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Oct 08 13:02:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333229, encodeId=d60013332295b, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Oct 08 13:02:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040562, encodeId=1ed8104056249, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Oct 07 01:02:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1883904, encodeId=b76c18839049c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 08 23:02:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087602, encodeId=487c208e60296, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jan 05 17:02:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1315941, encodeId=ce6c1315941eb, content=<a href='/topic/show?id=134f14834f2' target=_blank style='color:#2F92EE;'>#PTEN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14834, encryptionId=134f14834f2, topicName=PTEN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Oct 08 13:02:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333229, encodeId=d60013332295b, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Tue Oct 08 13:02:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040562, encodeId=1ed8104056249, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Mon Oct 07 01:02:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2019-10-07 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0